醒脑静联合依达拉奉治疗脑出血对患者VEGF、BNP及和肽素水平的影响

doi:10.3969/j.issn.1671-7171.2021.06.024

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1115 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To analyze the effect of Xingnaojing combined with edaravone on the levels of vascular endothelial growth factor (VEGF), brain natriuretic peptide (BNP) and copeptin in patients with cerebral hemorrhage. 【Methods】A total of 96 patients with cerebral hemorrhage were selected and divided into the control group and the observation group according to different treatment methods. Both groups were given conventional treatments. Patients in the control group were treated with Xingnaojing alone, while patients in the observation group were treated with Xingnaojing assisted by edaravone. The clinical efficacy of the two groups were analyzed after treatment.【Results】The total effective rate of patients in the observation group was 95.83% (46/48), which was higher than that of the control group 75.00% (36/48, P<0.05). There was no significant difference in the levels of indicators between the two groups before treatment (P>0.05). After treatment, the levels of ET, VEGF, BNP, copeptin, SF, NO, and MDA in the two groups were lower than those before treatment; and the above indicators in the observation group were lower than those in the control group after treatment. The difference was statistically significant (P<0.05). Before treatment, there was no statistically significant difference between the two groups in terms of of NIHSS, MoCA (the Montreal cognitive assessment scale), and ADL (activity of daily living scale) scores (P>0.05). After treatment, the NIHSS scores of the two groups were lower than those before treatment, and MoCA and ADL scores were higher than those before treatment. The NIHSS, MoCA and ADL scores of the observation group after treatment were better than those of the control group (P<0.05). 【Conclusion】Xingnaojing combined with edaravone therapy can improve the efficacy of cerebral hemorrhage, reduce the levels of BNF, copeptin, SF, NO, and MDA in patients, and improve the neurological function of patients. It is worthy of clinical application.

Key words： Cerebral Hemorrhage/TH Antipyrine/AA Natriuretic Peptide, Brain Vascular Endothelial Growth Factor A Peptides

Received: 02 January 2020

PACS:

R743.34

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIA Nan-jie
	FENG Jun-jie

Cite this article:

JIA Nan-jie,FENG Jun-jie. Effect of Xingnaojing Combined with Edaravone on the Levels of VEGF, BNP and Copeptin in Patients with Cerebral Hemorrhage[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(6): 890-892.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.06.024 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I6/890

[1] 胡荣,冯华.典型脑疾病——自发性脑出血研究进展与新理念[J].科技导报,2017,35(4):18-22.
[2] 任军伟,吴惺.自发性脑出血患者的颅内压、脑灌注压与血压调控研究进展[J].国际神经病学神经外科学杂志,2016,43(3):251-254.
[3] 王希佳.依达拉奉联合尼莫地平治疗高血压脑出血对神经功能和血肿及水肿的影响[J].河北医药,2016,6(4):547-549.
[4] 陈爱男,张志明,祝兆林,等.醒脑静联合纳洛酮对脑出血意识障碍患者的促醒作用[J].中国中西医结合急救杂志,2016,23(6):649-650.
[5] 中华人民共和国卫生部.成人自发性脑出血诊断标准[M].北京:人民卫生出版社,2010:1-6.
[6] 陈斌,成宜军,陈正鸿,等.脑出血后神经细胞死亡机制的研究进展[J].中国脑血管病杂志,2018,15(3):153-156.
[7] 李玉莲,刘春燕.醒脑静注射液联合依达拉奉治疗急性脑出血的疗效及对患者神经功能的影响[J].中国实用神经疾病杂志,2016,19(16):64-66.
[8] 黄伟贞.出血性中风病急性期中经络证、中脏腑证与脑 CT 征象的相关性分析[J].现代中西医结合杂志,2016,25(22):2395-23981.
[9] 师仰宏,霍艳艳.依达拉奉联合醒脑静对急性脑出血患者GCS及NIHSS评分的影响[J].海南医学,2017,28(13):2092-2094.
[10] 王伟伟,康玲,田永清,等.醒脑静联合依达拉奉治疗高血压脑出血的疗效分析[J].广西医科大学学报,2017,34(3):445-447.
[11] GEISELER S J, MORLAND C.The janus face of VEGF in stroke.[J].Int J Mol Sci,2018, 19(5):1362.
[12] 匡涛,刘旭,朱家伟,等.脑出血患者血清基质金属蛋白酶和氧化-抗氧化因子的动态变化研究[J].重庆医学,2016,45(32):4558-4561.
[13] 孙晓莉,武岳,秦敏,等.依达拉奉治疗急性脑出血的疗效及其对脑钠肽、和肽素水平的影响[J].疑难病杂志,2016,15(12):1215-1218.
[14] 曾劲松,葛金文.脑出血后铁代谢异常[J].国际脑血管病杂志,2017,25(5):443-448.